Published in TB and Outbreaks Week, June 10th, 1996
The grants, totaling $1.3 million over two years, are for the use of further development of the company's proprietary drug discovery technology and for the identification of specific small molecule drug candidates to treat and control these two highly pathogenic microorganisms.
The SBIR grants are funded by the U.S. Small Business Administration and administered by the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.